267 related articles for article (PubMed ID: 22064070)
1. Detection of peri-synaptic amyloid-β pyroglutamate aggregates in early stages of Alzheimer's disease and in AβPP transgenic mice using a novel monoclonal antibody.
Mandler M; Rockenstein E; Ubhi K; Hansen L; Adame A; Michael S; Galasko D; Santic R; Mattner F; Masliah E
J Alzheimers Dis; 2012; 28(4):783-94. PubMed ID: 22064070
[TBL] [Abstract][Full Text] [Related]
2. Glutaminyl cyclase contributes to the formation of focal and diffuse pyroglutamate (pGlu)-Aβ deposits in hippocampus via distinct cellular mechanisms.
Hartlage-Rübsamen M; Morawski M; Waniek A; Jäger C; Zeitschel U; Koch B; Cynis H; Schilling S; Schliebs R; Demuth HU; Rossner S
Acta Neuropathol; 2011 Jun; 121(6):705-19. PubMed ID: 21301857
[TBL] [Abstract][Full Text] [Related]
3. Novel monoclonal antibody 3B8 specifically recognizes pyroglutamate-modified amyloid β 3-42 peptide in brain of AD patients and 3xTg-AD transgenic mice.
Acero G; Garay C; Venegas D; Ortega E; Gevorkian G
Neurosci Lett; 2020 Apr; 724():134876. PubMed ID: 32114116
[TBL] [Abstract][Full Text] [Related]
4. Pyroglutamate-Aβ: role in the natural history of Alzheimer's disease.
Gunn AP; Masters CL; Cherny RA
Int J Biochem Cell Biol; 2010 Dec; 42(12):1915-8. PubMed ID: 20833262
[TBL] [Abstract][Full Text] [Related]
5. Heterogeneous Association of Alzheimer's Disease-Linked Amyloid-β and Amyloid-β Protein Precursor with Synapses.
Willén K; Sroka A; Takahashi RH; Gouras GK
J Alzheimers Dis; 2017; 60(2):511-524. PubMed ID: 28869466
[TBL] [Abstract][Full Text] [Related]
6. Immunohistochemical Evidence from APP-Transgenic Mice for Glutaminyl Cyclase as Drug Target to Diminish pE-Abeta Formation.
Hartlage-Rübsamen M; Bluhm A; Piechotta A; Linnert M; Rahfeld JU; Demuth HU; Lues I; Kuhn PH; Lichtenthaler SF; Roßner S; Höfling C
Molecules; 2018 Apr; 23(4):. PubMed ID: 29673150
[TBL] [Abstract][Full Text] [Related]
7. Pyroglutamate Abeta pathology in APP/PS1KI mice, sporadic and familial Alzheimer's disease cases.
Wirths O; Bethge T; Marcello A; Harmeier A; Jawhar S; Lucassen PJ; Multhaup G; Brody DL; Esparza T; Ingelsson M; Kalimo H; Lannfelt L; Bayer TA
J Neural Transm (Vienna); 2010 Jan; 117(1):85-96. PubMed ID: 19823761
[TBL] [Abstract][Full Text] [Related]
8. Mitochondria-targeted catalase reduces abnormal APP processing, amyloid β production and BACE1 in a mouse model of Alzheimer's disease: implications for neuroprotection and lifespan extension.
Mao P; Manczak M; Calkins MJ; Truong Q; Reddy TP; Reddy AP; Shirendeb U; Lo HH; Rabinovitch PS; Reddy PH
Hum Mol Genet; 2012 Jul; 21(13):2973-90. PubMed ID: 22492996
[TBL] [Abstract][Full Text] [Related]
9. The inside-out amyloid hypothesis and synapse pathology in Alzheimer's disease.
Gouras GK; Willén K; Faideau M
Neurodegener Dis; 2014; 13(2-3):142-6. PubMed ID: 24080821
[TBL] [Abstract][Full Text] [Related]
10. I716F AβPP mutation associates with the deposition of oligomeric pyroglutamate amyloid-β and α-synucleinopathy with Lewy bodies.
Sieczkowski E; Milenkovic I; Venkataramani V; Giera R; Ströbel T; Höftberger R; Liberski PP; Auff E; Wirths O; Bayer TA; Kovacs GG
J Alzheimers Dis; 2015; 44(1):103-14. PubMed ID: 25182745
[TBL] [Abstract][Full Text] [Related]
11. Immunomodulation of AβPP processing alleviates amyloid-β-related pathology in Alzheimer's disease transgenic mice.
Arbel-Ornath M; Becker M; Rabinovich-Toidman P; Gartner M; Solomon B
J Alzheimers Dis; 2010; 22(2):469-82. PubMed ID: 20847413
[TBL] [Abstract][Full Text] [Related]
12. Pyroglutamate-3 amyloid-β deposition in the brains of humans, non-human primates, canines, and Alzheimer disease-like transgenic mouse models.
Frost JL; Le KX; Cynis H; Ekpo E; Kleinschmidt M; Palmour RM; Ervin FR; Snigdha S; Cotman CW; Saido TC; Vassar RJ; St George-Hyslop P; Ikezu T; Schilling S; Demuth HU; Lemere CA
Am J Pathol; 2013 Aug; 183(2):369-81. PubMed ID: 23747948
[TBL] [Abstract][Full Text] [Related]
13. Effector function of anti-pyroglutamate-3 Aβ antibodies affects cognitive benefit, glial activation and amyloid clearance in Alzheimer's-like mice.
Crehan H; Liu B; Kleinschmidt M; Rahfeld JU; Le KX; Caldarone BJ; Frost JL; Hettmann T; Hutter-Paier B; O'Nuallain B; Park MA; DiCarli MF; Lues I; Schilling S; Lemere CA
Alzheimers Res Ther; 2020 Jan; 12(1):12. PubMed ID: 31931873
[TBL] [Abstract][Full Text] [Related]
14. Glutaminyl cyclase in human cortex: correlation with (pGlu)-amyloid-β load and cognitive decline in Alzheimer's disease.
Morawski M; Schilling S; Kreuzberger M; Waniek A; Jäger C; Koch B; Cynis H; Kehlen A; Arendt T; Hartlage-Rübsamen M; Demuth HU; Roßner S
J Alzheimers Dis; 2014; 39(2):385-400. PubMed ID: 24164736
[TBL] [Abstract][Full Text] [Related]
15. Pyroglutamate-modified amyloid-β protein demonstrates similar properties in an Alzheimer's disease familial mutant knock-in mouse and Alzheimer's disease brain.
Wu G; Miller RA; Connolly B; Marcus J; Renger J; Savage MJ
Neurodegener Dis; 2014; 14(2):53-66. PubMed ID: 24158021
[TBL] [Abstract][Full Text] [Related]
16. Glutaminyl cyclase inhibition attenuates pyroglutamate Abeta and Alzheimer's disease-like pathology.
Schilling S; Zeitschel U; Hoffmann T; Heiser U; Francke M; Kehlen A; Holzer M; Hutter-Paier B; Prokesch M; Windisch M; Jagla W; Schlenzig D; Lindner C; Rudolph T; Reuter G; Cynis H; Montag D; Demuth HU; Rossner S
Nat Med; 2008 Oct; 14(10):1106-11. PubMed ID: 18836460
[TBL] [Abstract][Full Text] [Related]
17. Pyroglutamate amyloid-β (Aβ): a hatchet man in Alzheimer disease.
Jawhar S; Wirths O; Bayer TA
J Biol Chem; 2011 Nov; 286(45):38825-32. PubMed ID: 21965666
[TBL] [Abstract][Full Text] [Related]
18. Distinct glutaminyl cyclase expression in Edinger-Westphal nucleus, locus coeruleus and nucleus basalis Meynert contributes to pGlu-Abeta pathology in Alzheimer's disease.
Morawski M; Hartlage-Rübsamen M; Jäger C; Waniek A; Schilling S; Schwab C; McGeer PL; Arendt T; Demuth HU; Rossner S
Acta Neuropathol; 2010 Aug; 120(2):195-207. PubMed ID: 20383514
[TBL] [Abstract][Full Text] [Related]
19. Tg-SwDI transgenic mice exhibit novel alterations in AbetaPP processing, Abeta degradation, and resilient amyloid angiopathy.
Van Vickle GD; Esh CL; Daugs ID; Kokjohn TA; Kalback WM; Patton RL; Luehrs DC; Walker DG; Lue LF; Beach TG; Davis J; Van Nostrand WE; Castaño EM; Roher AE
Am J Pathol; 2008 Aug; 173(2):483-93. PubMed ID: 18599612
[TBL] [Abstract][Full Text] [Related]
20. Alzheimer's disease.
De-Paula VJ; Radanovic M; Diniz BS; Forlenza OV
Subcell Biochem; 2012; 65():329-52. PubMed ID: 23225010
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
